Company news

Avecho Biotechnology Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

September 2023 Quarterly Activities Report & Appendix 4C

October 30, 2023

Reinstatement to Official Quotation

August 28, 2023

Avecho raises further $6M for Phase III trial

August 28, 2023

Voluntary Suspension

August 24, 2023

June 2023 Quarterly Activities Report & Appendix 4C

July 24, 2023

AVE CBD capsule passes two-year stability milestone

June 21, 2023

AVE adds TPM cannabinoid gummies to portfolio

June 6, 2023

USPTO allows new TPM manufacturing patent

May 28, 2023

Avecho licenses TPM for use in cancer drugs

May 22, 2023

AVE commences manufacturing for Phase III trial

May 16, 2023

Results of Entitlement Offer

May 8, 2023

March 2023 Quarterly Activities Report & Appendix 4C

April 27, 2023

Investor Presentation

April 3, 2023

Prospectus

April 3, 2023

Entitlement Offer to raise $11m for Phase 3 clinical trial

April 3, 2023

Clinical CBD program expands with the Lambert Initiative

February 21, 2023

December 2022 Quarterly Activities Report & Appendix 4C

January 30, 2023

Athenex submits Avechos phytonadione to FDA pre-IND

January 12, 2023

Avecho receives ethics approval for Phase III CBD trial

December 21, 2022

AVE signs development agreement with Perrigo

December 19, 2022

September 2022 Quarterly Activities Report & Appendix 4C

October 27, 2022

Increased CBD absorption in dogs vs commercial comparator

September 19, 2022

June 2022 Quarterly Activities Report & Appendix 4C

July 28, 2022

Security Class Reinstatement to Quotation- AVEO

July 14, 2022

Update on Listed Options and Federal Court Application

July 14, 2022

Suspension from Official Quotation - AVEO

June 8, 2022

March 2022 Quarterly Activities Report & Appendix 4C

April 28, 2022

Positive results from AVEs topical CBD pain study

March 28, 2022

Dosing begins in topical CBD pain study

February 28, 2022

Appendix 4E and Annual Report 31 December 2021

February 27, 2022

AVE license agreement for US recreational cannabis market

February 2, 2022

December 2021 Quarterly Activities Report & Appendix 4C

January 30, 2022

Application for quotation of securities - AVE

January 9, 2022

AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis

December 20, 2021

Positive results from Avechos Phase I trial of CBD soft-gel

December 7, 2021

September 2021 Quarterly Activities Report & Appendix 4C

October 28, 2021

Topical CBD pain study with Lambert Initiative approved

October 20, 2021

Dosing begins in Phase I PK trial testing CBD soft-gel

October 3, 2021

Phase I clinical trial testing CBD product-enrolment begins

September 14, 2021

June 2021 Quarterly Activities Report & Appendix 4C

July 26, 2021

Avecho to Present New CBD Data at GCI Virtual Summit

June 8, 2021

Chairs Address and CEO Presentation

May 31, 2021

AB Vista to explore new TPM applications for Animal Health

May 30, 2021

TGA meeting for CBD soft-gel targeting insomnia

May 25, 2021

Avecho completes pharmaceutical CBD soft-gel product

May 20, 2021

March 2021 Quarterly Activities Report & Appendix 4C

April 28, 2021

Avecho receives ethics approval for CBD human trial

April 12, 2021

AVE receives firm commitment to raise $5.06 via placement

February 9, 2021

December 2020 Quarterly Activities Report & Appendix 4C

January 29, 2021

AVE begins Human Trial on CBD product

December 22, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 23 decks. Every deck is listed under its year.